Translating Complex Biotech Innovation into an Investor-Ready Deck
Biotech decks fail when they’re too scientific for investors and too shallow for experts. This one had to strike the balance. The brief A clinical-stage biotech company developing a multi-application therapeutic molecule needed an investor presentation for venture capital and strategic pharma partners. The science was strong. The story needed clarity. What I built Every … Read more